Journal
NEUROSURGERY CLINICS OF NORTH AMERICA
Volume 31, Issue 1, Pages 131-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.nec.2019.08.015
Keywords
Low back pain (LBP); Spine degeneration; Cell therapy; Gene therapy; Mammalian protein production platforms; Protein packaging cell lines; Growth factors; Transforming growth factor-beta (TGF-beta); GDF6
Categories
Funding
- Biotechnology and Biological Sciences Research Council
- Engineering and Physical Sciences Research Council
- Medical Research Council [MC_PC_14112 v.2]
- European Commission [305815, 625746]
- European Union [115770]
- European Structural and Social Funds (ES StruktUrines Paramos) through the Research Council of Lithuania (Lietuvos Mokslo Taryba) [09.3.3-LMT-K-712, 09.3.3-LMT-K-712-01-0157, DOTSUT-215]
- new funding programme: Attracting Foreign Researchers for Research Implementation (2018-2022) [0.2.2-LMTK-718-02-0022]
- Medical Research Council via the UK Regenerative Medicine Platform Hubs Acellular Approaches for Therapeutic Delivery [MR/K026682/1]
- MRC [MR/K026682/1] Funding Source: UKRI
Ask authors/readers for more resources
This article provides an evidence-based personal perspective on the future of cell and gene therapy for degenerative diseases of the intervertebral disc. This paper focuses on how mammalian protein production platforms and transfected and irradiated protein packaging cell lines may be used as cellular factories for overproduction of therapeutic proteins and proanabolic growth factors, particularly in the context of regenerative therapies. This paper also speculates on future opportunities and challenges in this area of research and how new innovations in biotechnology affect cell and gene therapy for degenerative diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
